Castle Biosciences, Inc. (CSTL)

On our desk, the Q2 2026 print presents a classic growth-versus-margin dilemma. While top-line revenue surged 20% to $103 million—keeping the annual guidance range of $340-350 million intact—we cannot ignore the deterioration in gross margins. Adjusted gross margins pulled back to 76.3% from 79.5% due to higher scaling volumes, and operating expenses pushed the company into a net loss of $2.1 million compared to net income of $4.5 million a year prior. Until operating leverage catches up with top-line growth, valuation multiples may remain compressed within its established trading channel.

From a risk-assessment standpoint, the primary regulatory bottleneck centers on Medicare coverage timelines for DecisionDx-SCC. Management noted there is no public commentary on data discussions with Medicare contractors, meaning investors could face a prolonged wait of up to a year following any future draft LCD posting. Additionally, as the TissueCypher franchise scales, early low-hanging fruit conversions are drying up, meaning future penetration will demand heavier marketing efforts and potentially elevated expenditures.

In our clinic and technical evaluations, Castle's molecular diagnostics suite—spanning DecisionDx-Melanoma, TissueCypher, and Esopredict—continues to serve an actionable role in dermatologic and gastroenterological disease management. However, clinical adoption protocols must heavily factor in ongoing payer dynamics and the lack of immediate visibility on reimbursement policies for newer tests. Stakeholders should track how efficiently the lab infrastructure handles scaling without continuing to pressure overall gross margins.